Celebrating Lp(a) Awareness Day 2022 today!
Randox are raising awareness for Lipoprotein(a), we want to drive awareness on tests that are available to you to decrease the risk of stroke, heart attack or other heart diseases.
Lp(a) is a risk factor for atherosclerosis and related diseases including CHD and stroke. It is increasingly recognised as the strongest known genetic risk factor for premature coronary artery disease. The biggest challenge that exists surrounding Lp(a) measurement is the heterogeneity of the apolipoprotein(a) isoforms, resulting in the underestimation or overestimation of Lp(a) concentrations.
Benefits of the Randox Lp(a) assay
WHO/IFCC reference material – The Randox Lp(a) assay is calibrated in nmol/l and traceable to the WHO/IFCC reference material (IFCC SRM 2B) and provides an acceptable bias compared with the Northwest Lipid Metabolism Diabetes Research Laboratory (NLMDRKL) gold standard method.
Dedicated calibrator & control available – Five point calibrator with accuracy-based assigned target values (in nmol/l) is available, accurately reflecting the heterogeneity of the apo(a) isoforms. Dedicated Lp(a) control is available offering a complete testing package.
Excellent correlation – A correlation coefficient of r=0.995 was displayed when the Randox method was compared against other commercially available methods.
Excellent precision – The Randox Lp(a) assay displayed a within run precision of <2.54%.
Liquid ready-to-use – The Randox Lp(a) assay is available in a liquid ready-to-use format for convenience and ease-of-use.
Applications available – Instrument-specific settings can be provided for a wide range of clinical chemistry analysers.
The biggest challenge that exists surrounding Lp(a) measurement is the heterogeneity of the apo(a) isoforms, resulting in the underestimation or overestimation of Lp(a) concentrations. In immunoassays, the variable numbers of repeated KIV-2 units in Lp(a) act as multiple epitopes. This is where standardisation across calibrators is vital. Unless the calibrants do have the same range of isoforms as test samples, those with higher numbers of the KIV-2 repeat, will represent with an overestimation in Lp(a) concentrations and those with smaller numbers of the KIV-2 repeat, will represent with an underestimation. The smaller isoforms are strongly associated with higher Lp(a) concentrations. Lack of standardisation of the calibrant would result in an underestimation of Lp(a) associated CVD risk. It is important to note that an Lp(a) immunoassay employing isoform insensitive antibodies does not exist.
DID YOU KNOW?
Lp(a) has been identified to be a key risk factor for cardiovascular complications in individuals with COVID-19!
It is well documented that pre-existing comorbidities such as diabetes and CVD are associated with greater severity and higher fatality rates in those with COVID-19. Those with either baseline elevated Lp(a) or those whose Lp(a) levels increased following infection from COVID-19, or both, maybe at a significantly increased risk of developing thromboses. Elevated Lp(a) levels may cause acute destabilisation of pre-existing but quiescent, atherosclerotic plaques, which could induce an acute myocardial infarction or stroke.
Identifying any possible health conditions that would relate to early signs of stroke, heart attack or other heart diseases will allow you to make any decisions on an appropriate diet, lifestyle changes and early treatment to reduce your risk of further problems.
For more information about Lp(a):
Visit our website: Lipoprotein(a) [Lp(a)] | Reagents | Randox Laboratories
Or email: firstname.lastname@example.org
Lipid EQA Scheme
Reagents Resource Hub
We develop a range of applications for the RX daytona/ imola/ daytona plus/ monaco analysers so that laboratories worldwide can enjoy the benefits of freedom of choice from an independent manufacturer, Randox Laboratories. We have a range of assays available for the RX daytona/ imola/ daytona plus/ monaco, and we are always developing more applications. If you don’t see the application you are looking for, please contact us to request an application.
All kits are produced to international standard and have ISO 13485 accreditation.
Existing customers can access IFU’s through Powerline.
Rx daytona/imola /daytona plus/monaco - Reagents
Complement Component 3 CRP Full Range (0.3-160mg/l) IgE CRP
Complement Component 4 CRP High Sensitivity IgG IgA IgM Rheumatoid Factor BASIC METABOLIC PROFILE
Calcium Creatinine Enzymatic Potassium CO2 Total
Creatinine (Jaffe) Sodium Chloride Glucose
Alkaline Phosphatase Calcium Phosphorus Total Protein
Cholesterol CRP Full Range (0.3-160mg/l) Direct LDL Cholesterol Myoglobin
CK-MB CRP High Sensitivity Heart-Type Fatty Acid Binding Protein (H-FABP) sLDL
CK-NAC Digoxin Homocysteine Triglycerides
CRP Direct HDL Cholesterol Lipoprotein (a) COMPREHENSIVE METABOLIC PROFILE
Albumin Direct Bilirubin Creatinine (Jaffe) Sodium
Alkaline Phosphatase Calcium Glucose Total Bilirubin
ALT Chloride Lactate Total Protein
AST (GOT) CO2 Total Potassium Urea
Cholesterol Direct HDL Cholesterol Glycerol Ranbut (Hydroxybutyrate)
Creatinine Enzymatic Direct LDL Cholesterol HbA1c/Hb Total Protein
Creatinine (Jaffe) Fructosamine Microalbumin Triglycerides
Cystatin C Glucose NEFA (Non-Esterified Fatty Acids) Urinary Protein
Calcium CO2 Total Magnesium Sodium (Direct / Nondirect)
Chloride (Direct / Nondirect) Lithium Potassium (Direct / Nondirect) HAEMOLYTIC ANAEMA
G-6-P-DH Haptoglobin LDH HEPATIC FUNCTION
Albumin Cholinesterase Haptoglobin Total Bilirubin
Aldolase Complement C3 IgA Total Protein
Alkaline Phosphatase Complement C4 IgG Transferrin
Alpha-1 Antitrypsin Direct Bilirubin IgM Transthyretin (Prealbumin)
ALT Gamma GT Iron (UIBC) Ammonia
GLDH Leucine Arylamidase (LAP) AST (GOT) Glycerol
LDH INFLAMMATION AND INFECTION
Acid Phosphatase ASO Lactate Alpha-1Acid Glycoprotein
CRP Rheumatoid Factor LIPIDS
Apolipoprotein A-I Apolipoprotein C-II Cholesterol Lipoprotein (a)
Apolipoprotein A-II Apolipoprotein C-III Direct HDL Cholesterol sLDL
Apolipoprotein B Apolipoprotein E Direct LDL Cholesterol Triglycerides
Alpha-1 Antitrypsin CRP Full Range (0.3-160mg/l) IgE CRP
CRP High Sensitivity Transthyretin (Prealbumin) NEUROLOGICAL DISORDERS (CSF)
IgA IgG IgM NUTRITIONAL STATUS
Albumin Iron Magnesium Transferrin
Copper Iron (UIBC) Potassium Transthyretin (Prealbumin)
Ferritin Lipase TIBC Zinc
Amylase LDH Pancreatic Amylase Glucose
Lipase RENAL FUNTION
Albumin Creatinine Enzymatic IgG Sodium
Ammonia Creatinine (Jaffe) LDH Phosphorus (Inorganic)
Beta-2 Microglobulin Cystatin C Magnesium Urinary Protein
Calcium Glucose Microalbumin Urea
Chloride HbA1c/Hb Potassium Uric Acid
Albumin Cholinesterase (Butyryl) HDL Superoxide Dismutase (Ransod)
Alkaline phosphatase CK-NAC Iron (UIBC) Sodium
ALT (GPT) CO2 Total Lactate Therapeutic drugs
Aldolase Copper Lactate dehydrogenase Total Protein
Ammonia Creatinine LDL Triglycerides
Amylase CRP Lipase Urea
AST (GOT) Canine CRP Magnesium Uric Acid
Bile acids Fructosamine NEFA (Non-esterified fatty acids) Urinary protein
Bilirubin Gamma-GT Phosphorus (Inorganic) Zinc
Calcium GLDH Potassium Chloride
Glucose Ranbut (Hydroxybutyrate) Cholesterol Glycerol
Glutathione Peroxidase (Ransel) TOXICOLOGY
Acetaminophen Gentamicin Phenytoin Valproic Acid
Carbamazepine Lithium Salicylate Digoxin
Phenobarbitol Theophyline Drugs of Abuse
Barbiturates Cocaine metabolite Ethanol Opiates
Benzodiazepines EDDP Methadone Cannabinoids
Ecstasy Methamphetamine SPECIFIC PROTEINS
Alpha-1 Antitrypsin ASO Cystatin C IgM
Alpha-1 Acid Glycoprotein Beta-2 Microglobulin Ferritin Lipoprotein (a)
Apolipoprotein A-I Ceruloplasmin Fructosamine Microalbumin
Apolipoprotein A-II Complement C3 Haptoglobin Myoglobin
Apolipoprotein B Complement C4 HbA1c/Hb Rheumatoid Factor
Apolipoprotein C-II CRP IgA Transthyretin (Prealbumin)
Apolipoprotein C-III CRP Full Range (0.3-160mg/l) IgE Transferrin
Apolipoprotein E CRP High Sensitivity IgG RESEARCH
Albumin Glutathione Reductase TIBC Uric Acid
Bilirubin Glutathione Peroxidase (Ransel) Total Antioxidant Status Ferritin
Superoxide Dismutase (Ransod) Transferrin Biotechnology
Glutamate Glutamine Food and Wine Testing
Acetic Acid Copper Glycerol Malic Acid
Ammonia Glucose Iron Potassium
Calcium Glucose/Fructose L-Lactic Acid Total Antioxidant Status
30 June 2021
SARS-CoV-2 Vascular & Multi-System Dysfunction Whitepaper Download
COVID-19, the disease caused by SARS-CoV-2, is an infectious disease caused by a newly discovered coronavirus. While many of whom become infected by the disease will experience mild to moderate cold or flu-like symptoms, those with health complications – such as autoimmune diseases, asthma, heart disease and diabetes – are at risk of developing serious illness and adverse outcomes.
As of September 2021, over 228 million COVID-19 cases have been confirmed worldwide, with an estimated one in six patients experiencing complications which could be life threatening, with over £116 billion spent by the UK government alone on measures to combat the disease. This drastic spending has been mirrored across the globe, with the significant economic burden expected to be suffered for generations to come.
The whitepaper provides a brief overview of the COVID-19 pandemic, before discussing vascular abnormalities and associated complications brought on by the virus, such as multi-system disfunction, acute respiratory disease syndrome (ARDS) and hepatic, renal & cardiovascular function.
Want to know more about Randox?
Contact us or visit our homepage to view more.
Our COVID-19 Products and Services
Why does Randox sponsor Equine Sports?
1 September 2021: Why does Randox sponsor Equine Sports?
Some may be wondering, why is a healthcare company so invested in the equine industry? Why would they sponsor the world’s most famous steeplechase – The Randox Grand National?
It’s a labour of love… Peter FitzGerald’s fond attachment to the equestrian world, together with 40 years’ experience in the in vitro diagnostics industry, was the perfect match.
Clinical diagnostics is at the heart of Randox and our experience and expertise has paved the way for the development of innovative and accurate diagnostic products for Equine Health.
You could say ‘it runs in our blood.’
With 70% of all medical decisions based on the analysis of blood, Randox are set to release the VeraSTAT-V, a stable-side Equine Serum Amyloid A test device designed to detect levels of inflammation in horse blood in a matter of minutes.
The ability to quickly detect and monitor your horse’s health, at the stable side, brings huge benefits to both horse and owner. Early detection of inflammatory states means treatment plans can start sooner, recovery periods are shorter, and the horse can return to work healthy much earlier.
When performance is key, monitoring inflammation is vital.
Whether it’s detecting inflammation related to joint injury, or screening for infection before or after transport, competition or surgery, the VeraSTAT-V is a valuable means to monitor Equine Health.
At Randox, we have enjoyed a long-standing partnership with the Jockey Club and will continue to deliver innovative diagnostics solutions to the Equine Industry for the years ahead.
Interested in finding out more?
Reagents | Syphilis
Quantative and qualitative results available
For choice and convenience
Stable to expiry when stored at 2-8°C
- Treponema Pallidum Haemagglutination Assay (TPHA) method
- Liquid ready-to-use reagents
- Stable to expiry when stored at 2-8°C
- Qualitative or quantitative results
What is the Syphilis assay used for?
Syphilis is a chronic, contagious and often congenital venereal disease caused by Treponema pallidum. Infection results from contact with moist surfaces, originating in lesions of the epithelial tissue of the skin and mucous membranes. If untreated the disease may result in irreversible changes in the cardiovascular and nervous system. Syphilis remains a disease of high incidence, despite advances in modern antibiotic therapy.
Applications for Roche Cobas 4000 / 6000 / 8000
We develop a range of applications for the Roche Cobas Series (4000 / 6000 / 8000) analysers so that laboratories worldwide can enjoy the benefits of freedom of choice from an independent manufacturer, Randox Laboratories.
Applications available for Roche Cobas
We have 69 reagents available for the Roche Cobas Series (4000 / 6000 / 8000), and are always developing more. If you don’t see the application you are looking for, please email us to request an application. All kits are produced to international standard and have ISO 13485 accreditation.
D-3 Hydroxybutyrate (Ranbut)
Fructosamine (Glycated Protein)
Glutathione Peroxidase (Ransel)
Rheumatoid Factor (RF)
Superoxide Dismutase (Ransod)
Total Antioxidant Status(TAS)
Total Iron Binding
Applications for Beckman Coulter AU Series
We develop a range of applications for the Beckman Coulter AU Series (400 / 480 / 600 / 640 / 680 / 2700 / 5400 / 5800 / DxC700AU) analysers so that laboratories worldwide can enjoy the benefits of freedom of choice from an independent manufacturer, Randox Laboratories.
Beckman Coulter AU Series Applications
We have 89 reagents available for the Beckman Coulter AU (400 / 480 / 600 / 640 / 680 / 2700 / 5400 / 5800 / DxC700AU) analysers, and are always developing more. If you don’t see the application you are looking for, please contact us to request an application. All kits are produced to international standard and have ISO 13485 accreditation.
CRP Full Range
CRP High Sensitivity
LD Lactate – Pyruvate
LD Pyruvate – Lactate
Rheumatoid Factor (RF)
Superoxide Dismutase (Ransod)
Total Antioxidant Status (TAS)
Total Iron Binding
Randox Cardiology Reagents Panel
Randox is a leading provider of diagnostic reagents for the assessment of cardiovascular disease risk. Our extensive menu of cardiac biomarkers within the cardiology reagents panel include: routine lipid tests such as Homocysteine, hsCRP, Apo A-I, Apo A-II, Apo B and Lp(a), as well as, unique assays for cardiac risk assessment including sdLDL Cholesterol, Apo C-II, Apo C-III and Apo E. Check out our benefits below.
Randox Cardiology Reagents
- CK-MB useful in patients with chest pain; Creatine Kinase is an enzyme produced in many different types of cells, of which high levels indicate muscle trauma or damage.
- Myoglobin, a small protein which leaks out of muscle cells after injury, is also considered a biomarker for the detection of Myocardinal Infraction.
- Routine lipid tests to determine the patient’s cholesterol and triglyceride levels – HDL Cholesterol, LDL Cholesterol, Total Cholesterol and Triglycerides
- Independent risk assessment tests such as sdLDL Cholesterol and Lipoprotein(a) to determine any genetic factors which may increase their risk of CVD. Please note, this is necessary even for patients who have good cholesterol levels
- Secondary tests, such as High Sensitivity CRP, in addition to risk assessment markers and lipid evaluation – secondary tests are important in predicting future cardiac events of individuals with no previous history of CVD and those deemed healthy as a result of primary tests; approximately half of all heart attacks occur in patients classified as low risk. In addition, they can also be used to evaluate the risk of a recurrent cardiac event
- Speciality tests include
- Homocysteine – elevated levels of homocysteine have been linked to various disease states including CVD. Extremely high levels are found in patients with homocystinuria, of which many suffer from early arteriosclerosis.
Introducing The Randox Lipids Panel
Cardiovascular disease (CVD) caused by atherosclerosis (arteriosclerosis) is the leading cause of morbidity and mortality in Western countries1. Atherosclerosis involves the hardening and narrowing of vessels in the systemic system. This process originates from the build-up of fatty deposits through a process known as atherogenesis. If the build-up increases, plaque rupturing may occur which may lead to myocardial infarction2.
The mission of the National Lipid Association (NLA) “is to enhance the practice of lipid management in clinical medicine”. NLA advocate advancing the current lipid testing profile. The current lipid panel consists of testing LDL cholesterol, HDL cholesterol and triglycerides, which only detects approximately 20% of all atherosclerotic cardiovascular disease (ASCVD) patients. Advanced lipid testing is recommended to optimise patient treatment3.
75% of circulatory risk factors are preventable4
1 in 4 deaths in the US is attributed to heart disease6
6 million people in the UK suffer from narrowing of the heart arteries5
How Can Randox Help With The Current Challenges
As the current lipid panel consists of testing LDL cholesterol, HDL cholesterol and triglycerides, which only detects approximately 20% of all coronary artery disease (CAD) patients, advanced lipid testing is recommended to optimise patient treatment. The Randox lipid profile encompasses niche and superior performance assays for the detection of conventional risk factors, as well as emerging biomarkers associated with further risk.
Apolipoprotein C-III (Apo C-III)
A niche product from Randox, Apo C-III deficiency has shown to increase the rate of triglyceride clearance from plasma by up to 7 fold. Apo C-III levels have been reported higher in several conditions such as type 2 diabetes, hyperbilirubinemia and decreased thyroid function.
Apolipoprotein E (Apo E)
A niche product from Randox, Apo E has been found to have an association with neurodegenerative conditions such as Alzheimer’s Disease and Multiple Sclerosis. A deficiency in Apo E gives rise to high levels of serum cholesterol and triglycerides, leading to premature atherosclerosis
HDL3 Cholesterol (HDL3-C)
A niche product from Randox, HDL3-C, a subclass of HDL-C, has an inverse correlation with CVD risk. Several clinical studies indicate that measuring these HDL-C subclasses better reflects primary and secondary CHD risk than measurement of total HDL-C, making it a significant independent biomarker for better risk profiling when used together with other risk markers.
Lipoprotein (a) (Lp(a))
A unique product from Randox, Lp(a) has proven to have a causal role in the premature development of atherosclerosis and CVD as elevated Lp(a) levels associate robustly and specifically with increased CVD risk. The Randox Lp(a) assay is one of the only methodologies on the market that detects the non-variable part of the Lp(a) molecule and therefore suffers minimal size related bias.
Small-dense LDL Cholesterol (sdLDL-C)
A niche product from Randox, sdLDL-C, a subtype of LDL cholesterol, can more readily permeate the inner arterial wall. Research indicates that individuals with a predominance of sdLDL-C have a 3-fold increased risk of myocardial infarction.
Liquid ready-to-use assays
The Randox lipid assays are available in a liquid ready-to-use format for convenience and ease of use. (The Triglycerides kit is also available in a lyophilised format).
Wide measuring ranges
The Randox lipid assays can comfortably detect levels outside of the healthy range for the accurate detection of abnormal levels, offering peace of mind in patient samples.
Excellent correlation with standard methods
The Randox lipid assays display excellent correlations when compared against standard methods, offering trust and confidence in results.
Applications are available
Applications are available detailing instrument-specific settings for the convenient use of the Randox lipid assays on a wide range of clinical chemistry analysers.
Cardiovascular disease (CVD) refers to disease of the heart or blood vessels. Heart disease encompasses a number of diseases that affect the heart. In contrast, vascular disease encompasses a number of diseases that affect the blood vessels. Circulatory health problems are the result of vascular disease. Developing problems within the vascular system can go undetermined and in some patients the problem may only become apparent when they experience a heart attack or stroke 7.
Atherogenesis and Atherosclerosis
Atherogenesis is a circulatory disease whereby atheromas are formed (plaque build-up) within the artery. Plaque is a combination of cholesterol, fat, calcium, lipids and other substances within the blood stream. As time progresses, the plaque hardens, narrowing the arteries. This is known as atherosclerosis. Consequently, blood flow through the narrowed artery is reduced, limiting the supply of blood to vital organs and bodily tissues. As atherogenesis can affect any artery within the body, different diseases may develop based on the artery that is affected. Such diseases include: coronary heart/artery disease, carotid artery disease, peripheral artery disease and chronic kidney disease8.
As atherogenesis and atherosclerosis causes plaque to build up and harden within the arteries precipitating thrombi, blood flow to the heart, brain, or the lower extremities is obstructed (depending on the artery affected). This can further develop into coronary heart/artery disease (heart), ischemic stroke (brain) or peripheral vascular disease (lower extremities). However, the most common and most discussed of these manifestations is coronary heart/artery disease9. These manifestations occur when the plaque ruptures. The risk of the plaque rupturing is determined by the type of plaque (composition) rather than the size of the plaque (volume) as only plaques that are rich in soft extracellular lipids are rupture-prone (vulnerable). Whilst most plaque ruptures are small causing an acute coronary event, the actual vulnerability of the plaque may change over time. Luckily, the vulnerable plaque components are most likely to regress with treatment10.
The processes of atherogenesis, atherosclerosis and plaque rupturing, if left undetected can a myocardial infarction (MI) or “heart attack” if the plaque build-up has occurred in the coronary artery11. MI occurs when the blood supply to heart is completely blocked by the formation of a clot or a blockage due to a loose piece of atheroma (plaque rupturing). If the blood supply to the heart is blocked the cells in the heart begin to die due to the lack of oxygen, causing chest pain (angina). The extent of the blockage and the amount of heart muscle affected will determine whether this malfunction will affect the hearts ability to pump blood12. The signs of atherogenesis, atherosclerosis and plaque rupturing can be subtle, and most heart attack victims may only feel symptoms in the days leading up to the attack. For 80% of people, the first sign of a heart attack is angina. Other symptoms to be aware of are shortness of breath, anxiety, sweating, light-headedness and temporary changes in vision 11.
Regular exercise has a major effect on your circulation and cardiovascular health. Moderate levels of exercise can increase blood flow and reduce the risk of poor circulatory health conditions such as atherosclerosis. Exercise promotes good circulation as it strengthens the heart muscles, lowing the resting heart rate and preventing the build-up of plaque in the arteries. It is important for those with current circulation problems to be vigilant while exercising to ensure they are not over exerting themselves13.
Know your healthy fats
Diet changes are important for improving circulatory health. Eating a variety of foods such as lean meats, vegetables, fruits, legumes and whole grains will aid in lowering lipid levels and keep them low. It is recommended that more unsaturated fats are consumed in comparison to saturated fats, as saturated fats raise sdLDL-C levels which can lead to an increased risk of atherosclerosis. On the other hand, unsaturated fats such as monounsaturated or polyunsaturated fats may increase HDL levels and are known as being ‘heart-healthy’. It is recommended to find healthier alternatives for certain foods such as butter and oil14.
Smoking can cause circulatory problems in several ways. Most notably it can cause the carotid arteries (arteries which supply oxygen to the brain) to become filled with plaque. Also, smoking can cause PAD by reducing adequate blood supply to the limbs which can lead to leg pain and possibly amputation. Quitting smoking has been proven to have positive effects on circulation: just 20 minutes after a cigarette, blood pressure decreases and oxygen levels return to normal. Within 24 hours, the chance of a heart attack will have already decreased and after 48 hours, nerve endings deeded by the habit are expected to regenerate, with sense of taste and smell improving also. A year after quitting, the risk of coronary heart disease (CHD) will be halved. After 15 years, a quitter’s risk of CHD is now similar to that of a person who has never smoked14.
Cardiology Testing Panel
Featured Reagent Home
Reagents Resource Hub
 Burnett, John R. Lipids, Lipoproteins, Atherosclerosis and Cardiovascular Disease. National Center for Biotechnology Information (NCBI). [Online] Clin Biochem Rev., 25 February 2004. [Cited: 3 December 2018.] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1853363/.
 Zimmermaann, Kim Ann. Circulatory Systenm: Facts, Function & Diseases. Live Science. [Online] 16 March 2018. [Cited: 3 December 2018.] https://www.livescience.com/22486-circulatory-system.html.
 National Lipid Association. National Lipid Association Releases Updated Recommendations on the Use of PCSK9 Inhibitors at the 15th Annual Scientific Session. [Online] no date. [Cited: 3 December 2018.] https://www.lipid.org/nla/national-lipid-association-releases-updated-recommendations-use-pcsk9-inhibitors-15th-annual.
 World Heart Federation. Driving Sustainable Action for Circulatory Health: Whitepaper for Circulatory Health. [Online] Global Coarlition for Circulatory Health, no date. [Cited: 30 November 2018.] https://www.world-heart-federation.org/wp-content/uploads/2018/11/White-Paper-for-Circulatory-Health.pdf.
 British Heart Foundation. Research into atherosclerosis: 4 scientists talk about their work. [Online] no date. [Cited: 30 November 2018.] https://www.bhf.org.uk/informationsupport/heart-matters-magazine/research/atherosclerosis..
 Centers for Disease Control and Prevention. Heart Disease Facts. [Online] 28 November 2017. [Cited: 4 December 2018.] https://www.cdc.gov/heartdisease/facts.htm.
 Cardiovascular Disease. NHS. [Online] NHS UK, September 15, 2018. [Cited: November 30, 2018.] https://www.nhs.uk/conditions/cardiovascular-disease/
 National Heart, Lunch, and Blood Institute. Atherosclerosis. [Online] no date. [Cited: 28 November 2018.] https://www.nhlbi.nih.gov/health-topics/atherosclerosis.
 Fog Bentzon, Jacob, et al. Mechanisms of Plaque Formation and Rupture. Circulation Research. [Online] 6 June 2014. [Cited: 29 November 2018.] https://www.ahajournals.org/doi/abs/10.1161/circresaha.114.302721.
 Falk, E. Why do plaques rupture? National Center for Biotechnology Information. [Online] Circulation, December 1992. [Cited: 29 November 2018.] https://www.ncbi.nlm.nih.gov/pubmed/1424049.
 MedBroadcast. Heart Attack (Myocardial Infarction, MI). [Online] no date. [Cited: 30 November 2018.] https://medbroadcast.com/condition/getcondition/heart-attack.
 Harvard Health Publications. Heart Attack (Myocardial Infarction. [Online] 10 September 2018. [Cited: 30 November 2018.] https://www.drugs.com/health-guide/heart-attack-myocardial-infarction.html.
 Bergeson Becco, Laine. How Exercise Affects Circulation (and Vice Versa). Experience Life. [Online] June 2017. [Cited: 4 December 2018.] https://experiencelife.com/article/how-exercise-affects-circulation-and-vice-versa/.
 Mayo Clinic. Top 5 lifestykle changes to improve your cholesterol. [Online] 11 August 2018. [Cited: 4 December 2018.] https://www.mayoclinic.org/diseases-conditions/high-blood-cholesterol/in-depth/reduce-cholesterol/art-20045935.
- May 2022
- March 2022
- February 2022
- January 2022
- December 2021
- November 2021
- October 2021
- September 2021
- August 2021
- July 2021
- June 2021
- May 2021
- April 2021
- March 2021
- February 2021
- January 2021
- December 2020
- November 2020
- October 2020
- September 2020
- August 2020
- July 2020
- June 2020
- May 2020
- April 2020
- March 2020
- February 2020
- January 2020
- December 2019
- November 2019
- October 2019
- September 2019
- August 2019
- July 2019
- June 2019
- May 2019
- April 2019
- March 2019
- February 2019
- January 2019
- December 2018
- November 2018
- October 2018
- September 2018
- August 2018
- July 2018
- June 2018
- May 2018
- April 2018
- March 2018
- February 2018
- January 2018
- December 2017
- November 2017
- October 2017
- September 2017
- August 2017
- July 2017
- June 2017
- May 2017
- April 2017
- March 2017
- February 2017
- January 2017
- December 2016
- November 2016
- October 2016
- September 2016
- August 2016
- July 2016
- June 2016
- May 2016
- April 2016
- March 2016
- February 2016
- January 2016
- December 2015
- July 2015
- June 2015
- May 2015
- April 2015
- March 2015
- February 2015
- January 2015
- December 2014
- November 2014
- October 2014
- September 2014
- July 2014
- June 2014